Loading...
Market
Market Share of Weight-Loss Jabs in the UK by End of 2024
5
Resolution / Starting Odds
Ozempic >50% • 25%
Ozempic 25-50% • 25%
Ozempic <25% • 25%
Other brands dominate • 25%
Market research reports, UK National Health Service data
Story
Weight-Loss Jabs Like Ozempic Reduce Heart Attack Risk by 20%, Study Finds
May 14, 2024, 08:23 AM
A major study has found that weight-loss jabs, such as Ozempic, can significantly reduce the risk of heart attacks and strokes, even in patients who do not lose weight. The study highlights that these anti-obesity jabs cut the risk of heart death by 20%, prompting calls from doctors and the UK’s leading cardiologist for millions of Britons to be prescribed these medications. The jabs are being hailed as the biggest breakthrough since statins, with medics suggesting they should be prescribed similarly to statins to improve cardiovascular health.
View original story
Similar markets
Ozempic gains over 30% market share • 25%
Ozempic gains 10-30% market share • 25%
Ozempic gains less than 10% market share • 25%
Ozempic loses market share • 25%
Widely adopted in over 50 countries • 25%
Adopted in 20-50 countries • 25%
Adopted in less than 20 countries • 25%
Not adopted widely • 25%
Top 10% • 25%
Top 25% • 25%
Top 50% • 25%
Below 50% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of World • 25%
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
Focused mostly on personal stories • 33%
Focused on policy and healthcare system • 33%
Balanced coverage of both • 34%